Genelux Co. (NASDAQ:GNLX) Major Shareholder Aladar Szalay Sells 33,080 Shares of Stock

Genelux Co. (NASDAQ:GNLX) major shareholder Aladar Szalay sold 33,080 shares of the firm’s stock in a transaction on Friday, September 13th. The shares were sold at an average price of $2.57, for a total value of $85,015.60. Following the transaction, the insider now owns 599,821 shares of the company’s stock, valued at $1,541,539.97. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Major shareholders that own 10% or more of a company’s stock are required to disclose their sales and purchases with the SEC.

Aladar Szalay also recently made the following trade(s):

• On Wednesday, September 11th, Aladar Szalay sold 31,376 shares of Genelux stock. The shares were sold at an average price of $2.62, for a total transaction of $82,205.12.
• On Monday, September 9th, Aladar Szalay sold 23,383 shares of Genelux stock. The stock was sold at an average price of $2.70, for a total transaction of $63,134.10.
• On Tuesday, September 3rd, Aladar Szalay sold 42,818 shares of Genelux stock. The shares were sold at an average price of $2.09, for a total transaction of $89,489.62.
• On Thursday, August 29th, Aladar Szalay sold 107,045 shares of Genelux stock. The shares were sold at an average price of $1.98, for a total value of $211,949.10.
• On Tuesday, August 27th, Aladar Szalay sold 51,630 shares of Genelux stock. The stock was sold at an average price of $2.11, for a total value of $108,939.30.
• On Friday, August 23rd, Aladar Szalay sold 40,000 shares of Genelux stock. The shares were sold at an average price of $2.29, for a total value of $91,600.00.

Genelux Stock Down 8.6 %

Shares of NASDAQ:GNLX opened at $2.44 on Friday. The firm’s 50 day moving average price is $2.21 and its 200-day moving average price is $3.44. The stock has a market capitalization of $84.25 million, a PE ratio of -2.52 and a beta of -1.55. Genelux Co. has a twelve month low of $1.60 and a twelve month high of $30.44.

Genelux (NASDAQ:GNLX) last issued its quarterly earnings results on Wednesday, August 14th. The company reported ($0.22) earnings per share for the quarter, missing the consensus estimate of ($0.19) by ($0.03). Analysts expect that Genelux Co. will post -0.9 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of brokerages have weighed in on GNLX. HC Wainwright reissued a “buy” rating and issued a $32.00 target price on shares of Genelux in a research report on Thursday, August 15th. Roth Capital raised shares of Genelux to a “strong-buy” rating in a report on Tuesday, August 27th. Roth Mkm started coverage on shares of Genelux in a report on Tuesday, August 27th. They issued a “buy” rating and a $10.00 target price on the stock. Finally, Benchmark decreased their target price on shares of Genelux from $30.00 to $25.00 and set a “speculative buy” rating for the company in a research note on Friday, May 31st. Four analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the stock presently has an average rating of “Buy” and a consensus price target of $22.33.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the stock. Point72 Asia Singapore Pte. Ltd. bought a new stake in Genelux during the 2nd quarter worth approximately $39,000. Cubist Systematic Strategies LLC bought a new stake in shares of Genelux in the 2nd quarter worth about $56,000. Miracle Mile Advisors LLC purchased a new position in Genelux in the second quarter worth about $58,000. New York State Common Retirement Fund increased its stake in Genelux by 17.6% during the fourth quarter. New York State Common Retirement Fund now owns 6,461 shares of the company’s stock worth $91,000 after acquiring an additional 966 shares during the last quarter. Finally, SageView Advisory Group LLC purchased a new stake in Genelux during the first quarter valued at approximately $121,000. Institutional investors own 37.33% of the company’s stock.

About Genelux

Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small cell lung cancer.